Search
Deuruxolitinib
go.drugbank.com/drugs/DB18847ApprovedInvestigationalDeuruxolitinib is a deuterated form of ruxolitinib that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the dur...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRibociclib
go.drugbank.com/drugs/DB11730ApprovedInvestigationalRibociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can e...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsCapmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigationalCapmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesNiraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First appr...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InducersBictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalBictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesErtugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 20...
Categories: P-glycoprotein substratesNirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalNirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. Desmoid tumors are typically characterized by aberrant activation in Notch signaling. Interaction between the n...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDefactinib
go.drugbank.com/drugs/DB12282ApprovedInvestigationalDefactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. FAK is important for the integrin-...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersRucaparib
go.drugbank.com/drugs/DB12332ApprovedInvestigationalRucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of a...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsSeladelpar
go.drugbank.com/drugs/DB12390ApprovedInvestigationalSeladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment o...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates